查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604899

中轴型脊椎关节炎市场：按类型、药物类别（抗风湿药、糖皮质激素、非类固醇消炎剂）、最终用户划分 - 2025-2030 年全球预测

Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis )), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs ), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年中轴型脊椎关节炎市值为53.2亿美元，预计2024年将达56.8亿美元，复合年增长率为7.42%，预计到2030年将达到87.9亿美元。

中轴型脊椎关节炎 (axSpA) 是一种慢性发炎疾病，主要影响脊椎和骶髂关节，导致疼痛和进行性僵硬。推进 axSpA 研究的必要性源于该疾病患病率的不断上升、认识不足以及对更有效治疗方法的需求。最终用途包括医疗设施、研究机构和製药公司。影响市场成长的主要因素包括疾病意识的提高、诊断影像的进步以及生技药品和生物相似药的推出。此外，遗传和环境因素在 axSpA 发病机制中的强烈参与导致人们对个人化医疗的兴趣日益浓厚，为客製化治疗创造了机会。对新型生物製药（包括 IL-17 和 JAK 抑制剂）的研究正在进行中，并提供了潜在的增长途径，同时透过基因分析和生物标记发现改进了治疗的个体化。然而，该市场也存在局限性，包括治疗成本高、生物製药潜在的副作用以及早期诊断的复杂性。此外，这种疾病的慢性性质给医疗保健系统带来了压力，凸显了对具有成本效益的管理解决方案的需求。进入该市场的公司正在投资开拓副作用较少的创新药物，加强对医疗保健提供者和患者的教育和宣导活动，并评估治疗的长期有效性和安全性，需要在临床试验中合作。监测疾病进展的数位健康工具、人工智慧在诊断准确性方面的整合以及非侵入性治疗方法的开发等领域的创新可能会蓬勃发展。因此，虽然 axSpA 市场面临挑战，但它也提供了切实的突破机会，可以重新定义患者照护和市场动态。

主要市场统计
基准年[2023] 53.2亿美元
预测年份 [2024] 56.8亿美元
预测年份 [2030] 87.9亿美元
复合年增长率（%） 7.42%

市场动态：快速发展的中轴型脊椎关节炎市场的关键市场洞察

供需的动态交互作用正在改变中轴型脊椎关节炎市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 关节炎和关节疼痛加剧
    • 增加研发活动
    • 政府和私人公司努力扩大关节炎的治疗选择
  • 市场限制因素
    • 产品或药品召回的发生
  • 市场机会
    • 中轴型脊椎关节炎个人化治疗进展
    • 针对中轴型脊椎关节炎的新型生物製药的出现
  • 市场挑战
    • 严格医药品认证过程规定

波特五力：驾驭中轴型脊椎关节炎市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解中轴型脊椎关节炎市场的外部影响

外部宏观环境因素在塑造中轴型脊椎关节炎市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解中轴型脊椎关节炎市场的竞争格局

对中轴型脊椎关节炎市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵中轴型脊椎关节炎市场供应商的绩效评估

FPNV 定位矩阵是评估中轴型脊椎关节炎市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了中轴型脊椎关节炎市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对中轴型脊椎关节炎市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 关节炎和关节痛的发生率增加
      • 增加研发活动
      • 政府和私人努力扩大关节炎的治疗选择
    • 抑制因素
      • 产品和药品回收数量
    • 机会
      • 中轴型脊椎关节炎个人化照护的进展
      • 治疗中轴型脊椎关节炎的新生物製药的出现
    • 任务
      • 严格药品核准流程规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章中轴型脊椎关节炎市场：依类型

  • 僵直性脊椎炎（AS）
  • 非放射性中轴型脊椎关节炎 (nr-axSpA)

第七章中轴型脊椎关节炎市场：依药物类别

  • 抗风湿药
  • 糖皮质激素
  • 非类固醇消炎剂(NSAID)

第 8 章 中轴型脊椎关节炎市场：依最终使用者分类

  • 学术研究所
  • 诊所
  • 医院
  • 復健中心

第九章北美和南美中轴型脊椎关节炎市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太中轴型脊椎关节炎市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的中轴型脊椎关节炎市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Inmagene Biopharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB SA
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market was valued at USD 5.32 billion in 2023, expected to reach USD 5.68 billion in 2024, and is projected to grow at a CAGR of 7.42%, to USD 8.79 billion by 2030.

Axial Spondyloarthritis (axSpA) is a spectrum of chronic inflammatory diseases primarily affecting the spine and the sacroiliac joints, leading to pain and progressive stiffness. The necessity of advancing research in axSpA stems from the increasing prevalence of the condition, inadequate awareness, and a demand for more effective treatments. Applications include improving diagnostic methods, refining therapeutic interventions, and tailored patient management to enhance quality of life, while end-use scope is seen in healthcare facilities, research institutes, and pharmaceutical companies. Key factors influencing market growth include rising awareness about the disease, advances in diagnostic imaging, and the introduction of biologics and biosimilars. Furthermore, the significant role of genetic and environmental factors in axSpA's etiology has stimulated interest in personalized medicine, creating opportunities for tailored therapeutics. Ongoing research into novel biologics, including IL-17 and JAK inhibitors, represents potential growth avenues, alongside improved treatment personalization through genetic profiling and biomarker exploration. Nonetheless, market limitations include high treatment costs, potential side effects of biologics, and the complexities of early diagnosis. Additionally, the chronic nature of the disease burdens healthcare systems, highlighting a need for cost-effective management solutions. Entities in this market are urged to invest in the development of innovative drugs with fewer side effects, expand education and awareness initiatives among healthcare providers and patients, and push for collaborative efforts in clinical trials to assess the long-term efficacy and safety of treatments. Innovation can thrive in areas like digital health tools for monitoring disease progression, the integration of AI in diagnostic precision, and the development of non-invasive therapies. Thus, while the axSpA market presents challenges, it simultaneously offers tangible opportunities for breakthroughs that can redefine patient care and market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.32 billion
Estimated Year [2024] USD 5.68 billion
Forecast Year [2030] USD 8.79 billion
CAGR (%) 7.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Axial Spondyloarthritis Market

The Axial Spondyloarthritis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of arthritis and joint pain
    • Growing number of research and development activities
    • Efforts by government and private players to expand treatment options for arthritis
  • Market Restraints
    • Incidences of product and drug recall
  • Market Opportunities
    • Advances in personalized care for axial spondyloarthritis
    • Emergence of novel biologic agents targeting axial spondyloarthritis
  • Market Challenges
    • Stringent regulations concerning the drug approval process

Porter's Five Forces: A Strategic Tool for Navigating the Axial Spondyloarthritis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Axial Spondyloarthritis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Axial Spondyloarthritis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Axial Spondyloarthritis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Axial Spondyloarthritis Market

A detailed market share analysis in the Axial Spondyloarthritis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Axial Spondyloarthritis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Axial Spondyloarthritis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Axial Spondyloarthritis Market

A strategic analysis of the Axial Spondyloarthritis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Axial Spondyloarthritis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Inmagene Biopharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)).
  • Based on Drug Class, market is studied across Anti-Rheumatic Drugs, Glucocorticoids, and Non-steroidal anti-inflammatory Drugs (NSAIDs).
  • Based on End User, market is studied across Academic Research Institutes, Clinics, Hospital, and Rehabilitation Center.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of arthritis and joint pain
      • 5.1.1.2. Growing number of research and development activities
      • 5.1.1.3. Efforts by government and private players to expand treatment options for arthritis
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product and drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in personalized care for axial spondyloarthritis
      • 5.1.3.2. Emergence of novel biologic agents targeting axial spondyloarthritis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning the drug approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Axial Spondyloarthritis Market, by Type

  • 6.1. Introduction
  • 6.2. Ankylosing Spondylitis (AS)
  • 6.3. Non-Radiographic Axial Spondyloarthritis (nr-axSpA))

7. Axial Spondyloarthritis Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Rheumatic Drugs
  • 7.3. Glucocorticoids
  • 7.4. Non-steroidal anti-inflammatory Drugs (NSAIDs)

8. Axial Spondyloarthritis Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Clinics
  • 8.4. Hospital
  • 8.5. Rehabilitation Center

9. Americas Axial Spondyloarthritis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Axial Spondyloarthritis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Axial Spondyloarthritis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Eli Lilly and Company
  • 5. Galapagos NV
  • 6. Inmagene Biopharmaceuticals
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
  • FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AXIAL SPONDYLOARTHRITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANKYLOSING SPONDYLITIS (AS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANTI-RHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023